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Abstract
Background: The p53 tumor suppressor gene is commonly mutated in colorectal cancer. While
the effect of p53 mutations on colorectal cancer prognosis has been heavily studied, less is known
about how epidemiologic risk factors relate to p53 status, particularly in early colorectal neoplasia
prior to clinically invasive colorectal cancer (including adenomas, carcinoma in situ (CIS), and
intramucosal carcinoma).
Methods: We examined p53 status, as measured by protein overexpression, in 157 cases with
early colorectal neoplasia selected from three New York City colonoscopy clinics. After collecting
paraffin-embedded tissue blocks, immunohistochemistry was performed using an anti-p53
monoclonal mouse IgG2a [BP53-12-1] antibody. We analyzed whether p53 status was different for
risk factors for colorectal neoplasia relative to a polyp-free control group (n = 508).
Results: p53 overexpression was found in 10.3%, 21.7%, and 34.9%, of adenomatous polyps, CIS,
and intramucosal cases, respectively. Over 90% of the tumors with p53 overexpression were
located in the distal colon and rectum. Heavy cigarette smoking (30+ years) was associated with
cases not overexpressing p53 (OR = 1.8, 95% CI = 1.1–2.9) but not with those cases
overexpressing p53 (OR = 1.0, 95% CI = 0.4–2.6). Heavy beer consumption (8+ bottles per week)
was associated with cases overexpressing p53 (OR = 4.0, 95% CI = 1.3–12.0) but not with cases
without p53 overexpression (OR = 1.6, 95% CI = 0.7–3.7).
Conclusion: Our findings that p53 overexpression in early colorectal neoplasia may be positively
associated with alcohol intake and inversely associated with cigarette smoking are consistent with
those of several studies of p53 expression and invasive cancer, and suggest that there may be
relationships of smoking and alcohol with p53 early in the adenoma to carcinoma sequence.
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Background
The molecular model of genetic changes along the color-
ectal adenoma-carcinoma sequence, first described by
Vogelstein and colleagues, has become the framework for
understanding the timing and role multiple mutations
and genetic alterations play in carcinogenesis [1]. It is
thought that multiple mutations are needed for invasive
cancer [1–4]. Although the number of mutations and not
their order has been found to be paramount, there are
general trends in terms of timing in the sequence. Of more
common genes important to colorectal carcinogenesis
(e.g., APC, K-ras, and p53), most data suggest that p53 is
generally mutated later in the adenoma-carcinoma
sequence [1,3–9]. The prevalence of p53 protein overex-
pression, which is highly correlated with p53 gene muta-
tions [10–12], increases along the adenoma-carcinoma
sequence with as little as 7.1 percent overexpression in
adenomas with mild dysplasia to over sixty percent in
those with severe dysplasia and invasive cancer [13–15].
Although the majority of colorectal cancers are thought to
originate from adenomas, most adenomas do not
progress to cancer. In fact, even though the prevalence of
adenomas in most high-risk populations is extremely
high (as high as 20 percent in people under 50 and over
50 percent among people in their 70s [16], colorectal can-
cer is still a rare event. Estimates of the cumulative risk of
invasive cancer after adenoma detected on screening exam
range from 1 to 10 percent depending on the length of fol-
low-up [16,17]. Apart from pathologic characteristics
such as larger size and villous histology, little is known
about risk factors for intermediate steps along the ade-
noma-carcinoma sequence such as carcinoma in situ (CIS)
and intramucosal carcinoma [18].
We undertook this investigation to examine if risk factors
for early colorectal neoplasia differed by p53 status. Spe-
cifically, we were interested in whether colorectal cancer
risk factors including alcohol use and cigarette smoking
are associated with p53 status in early colorectal neoplasia
and if these associations were similar to associations with
invasive colorectal cancer. If so, such findings would sug-
gest that processes contributing to the relationships
between risk factors and p53 protein overexpression begin
early in the adenoma-carcinoma sequence and may point
to factors to target for intervention and future prevention.
We conducted two analyses, one combining all cases of
early colorectal neoplasia (subjects with adenomatous
polyps, carcinoma in situ (CIS), and intramucosal carci-
noma (IM)) and a second examining only cases with
advanced adenomas (subjects with CIS and IM). Together
these case groups represent steps along the adenoma car-
cinoma sequence prior to clinically relevant invasive
colorectal cancer.
Methods
Study population
The cases and controls for this study come from a case-
control study of newly diagnosed adenomas and polyp-
free controls conducted in three New York City colonos-
copy clinics between April 1986 to March 1988 [19,20].
Both the parent study and this study were approved by
Columbia's Institutional Review Board. There were 3,008
individuals who underwent colonoscopy during this time
frame at the three colonoscopy clinics, of whom 2,443
(81.2%) were eligible to participate in this study. To be
eligible, the subjects in this study were required to have
had a complete colonoscopy; to be English- or Spanish-
speaking; and to be between the ages of 35 and 84 years
(18.8% of the subjects were not eligible because of incom-
plete colonoscopy, language restrictions and or age restric-
tions). Of the 2,443 eligible subjects, 2,001 subjects
(81.9%) were successfully interviewed, both by telephone
(71%) and by mailed questionnaire (29%) with follow-
up telephone calls to complete incomplete items. The
questionnaire contained information on demographics,
past medical history, dietary habits, alcohol intake, smok-
ing history, body size, physical activity, and other lifestyle
factors.
The 2,001 interviewed subjects were subdivided into sev-
eral categories, based on the diagnosis at the index colon-
oscopy and after a uniform pathologic review. Of these
2,001 subjects, there were 508 subjects free of any polyp
(including adenomatous and hyperplastic) with a normal
index colonoscopy and no prior history of colorectal neo-
plasia, 269 subjects with newly diagnosed adenoma, with
no prior history of colorectal neoplasia, 57 carcinoma in
situ (CIS) cases with or without a known history of adeno-
mas, and 58 intramucosal carcinoma cases with or with-
out a known history of adenomas (n = 58). The remaining
subjects (n = 1,109) had pathologic diagnoses that were
not of interest to this current investigation including
hyperplastic polyps. For this study of early colorectal neo-
plasia, we collected paraffin-embedded tumor tissue
blocks for the cases with intramucosal carcinoma, carci-
noma in situ (CIS) and a random sample of cases with
adenomatous polyps. Blocks with enough tissue for
immunohistochemistry were retrieved for 46 (80%) of
the CIS cases, 43 (75%) of the IM cases and a random
sample of 25% of the adenomatous polyp cases (n = 68)
frequency-matched by age (within 5 years) and sex to the
other case groups. Risk factor data were not statistically
significantly different between those with tumor blocks
available and those without (data not shown). The cases
were compared with polyp-free controls (n = 508).
Immunohistochemistry
Immunohistochemistry[21] was performed on using five
:m formalin-fixed, paraffin-embedded tissue sections,BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
Page 3 of 9
(page number not for citation purposes)
placing them on silane-coated slides and baking at 60° for
30 minutes. Afterwards, the slides are de paraffinized,
hydrated, place in 10 mM citrate buffer (pH 6) and micro-
waved for a total of ten minutes (antigen retrieval).
Appropriate blocking serum (Horse serum) and an anti-
p53  monoclonal Mouse IgG2a [BP53-12-1] antibody
(1:300 dilution, BioGenex, San Ramon, CA) was used.
Detection method used Vectastain, Elite ABC kit (Vector
Laboratory, Burlington, CA). Chromogen diamino-benzi-
dine was used and sections were counter-stained with
methyl green (Ethyl Green; Sigma Chemical Co; St. Louis
MO). Nuclear staining of tumor tissue, from a single slide,
was evaluated by a semiquantitative scoring system for
intensity and percent positive nuclei. A positive control
with known strongly positive p53 staining was used for
comparison in each batch. Adjacent non-neoplastic
colonic epithelium was used as a negative control for each
batch. Two study pathologists (HH and MM) blinded to
case status reviewed the stained slides and scored each
case based on staining intensity and percent of cells on
slide showing evidence of overexpression. Disagreements
in ratings were resolved by consensus of the two patholo-
gists. The following categories were used for scoring:
intensity (None, Mild, Moderate, and Strong) and percent
positive (none or rare, < 10% nuclear staining, 10–25%,
25–50%, and >50%). Cutoff levels reflect levels of stain-
ing not observed in normal colonic mucosa controls.
Cases were classified as positive if the intensity score was
strong and at least 10% or more of cells showing evidence
of overexpression. For ease of presentation, we refer to
these cases with protein overexpression as p53+ cases
throughout the manuscript; those cases with no, mild or
moderate staining intensity with any percent positive or
those with strong staining but less than 10% positive
nuclear staining are referred to as p53- cases. We also per-
formed sensitivity analyses on the final models using a
more stringent (intensity score strong and at least 25% or
more of cells showing evidence of overexpression) as well
as a less stringent definition (intensity score of moderate
or strong with at least 10% or more of cells showing evi-
dence of overexpression) of positivity.
Statistical methods
First, univariate analyses comparing epidemiologic risk
factors and p53 status were performed using analysis of
variance for continuous variables and chi-square tests for
categorical variables. All continuous variables were then
categorized based on quantiles in the control group to test
for linearity with respect to outcome status. Second, we
used unordered polytomous logistic regression models to
adjust for potential confounding variables [22]. We per-
formed two separate analyses: the first, combined all three
groups (adenomas, CIS, and IM) into a single case group
of early colorectal neoplasia; the second, examined only
examined advanced adenomas (CIS and IM). Our sample
size limited the use of multivariate models to analyze each
type of case separately by p53 status, though univariate
analyses suggested that the association between risk fac-
tors and p53 status were similar in magnitude across the
separate types of cases (adenomas, CIS, and IM) (data not
shown). There were a total of three outcome categories:
p53 + cases, p53 - cases, and polyp-free controls and com-
parisons where made using odds ratios (OR) and 95%
confidence intervals (CI) for p53+ cases versus polyp-free
controls, p53- cases versus controls, and p53+ versus p53-
cases.
All continuous variables that did not have a linear rela-
tionship with outcome status were categorized in catego-
ries based on homogeneity in risk [23]. To account for the
non-linear relationship with age, age adjustments were
made by adding age and age squared (age2) to the regres-
sion model. Model building was based on log likelihood
tests [22]. Heterogeneity by p53 status was examined by
examining the ratio of the odds ratio (which is equivalent
to exponentiating the difference in the beta coefficients)
and the 95% CI (based on the variance for the difference
in the beta coefficients)[22].
Results
The prevalence of p53 protein overexpression increased
steadily across the adenoma-carcinoma sequence from
10.3%, 21.7%, and 34.9% for adenomatous polyps, CIS,
and intramucosal carcinoma (IM), respectively. Although,
p53 protein overexpression differed by type of case group
(p < .01), univariate associations between risk factors
(including family history, alcohol use, tobacco use, body
size, physical activity, dietary fiber and fat) and p53 status
did not differ in magnitude or direction for the three types
of cases, albeit numbers were small. Because of these sim-
ilar univariate association and because of statistical power
constraints we conducted two main multivariate analyses,
one combining the three types of cases (adenomas, CIS,
and IM) and a second only examining the more advanced
adenomas (CIS and IM).
Univariate differences in risk factors by p53  status are
reported in Table 1. In this table we combined cases of
adenomatous polyps, CIS, and IM and then stratified
based on p53 status. There were no statistically significant
differences in risk factors stratified by p53 status though
subjects with no overexpression tended to smoke for more
years with greater intensity and subjects with overexpres-
sion tended to drink more. Over 90% of the polyps over-
expressing  p53  were located in the rectum and distal
colon. The comparison of p53 status by major polyp site
(rectum, distal, and proximal) was statistically significant
(p < 0.01). The prevalence of p53 protein overexpression
by polyp site was 32%, 27%, and 6% for rectum, distal,
and proximal colon, respectively.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
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Age-adjusted odds ratios from unordered polytomous
logistic regression models are presented in Table 2. Long
term cigarette smoking (30+ years) was associated with
cases whose tumors that did not overexpress the p53 pro-
tein (OR = 1.8, 95% CI = 1.1–2.9) but not with cases with
tumors that overexpressed the p53 protein (OR = 1.1, 95%
CI 0.4–2.8), relative to polyp free controls. In contrast,
heavy beer consumption (8+ bottles per week) was
stronger for cases whose tumors overexpressed the p53
protein (OR = 4.5, 95%CI = 1.6–12.4) than for those cases
without p53 protein (OR = 2.2, 95% CI = 1.0–4.7). Risk
factors for colorectal neoplasia, other than alcohol and
cigarette smoking, did not vary by p53 status.
The multivariate adjusted model, reported in Table 3
(panel A), found similar associations to the age-adjusted
models. Long term cigarette smokers (30+ years) had an
80% (OR = 1.8, 95% CI = 1.1–2.9) increase in risk of ade-
nomatous polyps (with and without CIS and IM) that do
not overexpress p53 protein relative to polyp-free controls.
Heavy beer consumers (8+ bottles per week) had 4 times
the risk (OR = 4.0, 95% CI = 1.3–12.0) of adenomatous
polyps (with and without CIS and IM) that overexpress
p53 protein relative to polyp-free controls.
We also examined these associations for only the cases of
CIS and IM. These findings are also reported in Table 3
(panel B) and suggest little differences between the
analyses for all three groups combined. Although these
results suggest that cigarette smoking may be associated
mainly with the tumors that do not overexpress p53 pro-
tein and beer consumption mainly with the tumors that
overexpress p53 protein, statistical tests of heterogeneity
were not significant (see the case/case comparisons
reported in Table 3). Specifically, the comparison of heavy
beer consumption for subjects with polyps that overex-
Table 1: Descriptive Statistics by p53 status.
No p53 protein overexpression (n = 125) p53 protein overexpression (n = 32) P value*
Sex
Male 66(52.8%) 16 (50%) 0.77
Female 59 (47.2%) 16 (50%)
Age (µ µ ;± σ) 65.7 (8.6) 67.8 (9.5) 0.23
Race
White 103 (83.1%) 30 (93.8%) 0.24
Black 12 (9.7%) 2 (6.2%)
Other 9 (7.3%) 0 (0%)
Family History of Colorectal Cancer
Yes 28 (22.4%) 5(15.6%) 0.40
No 97 (77.6%) 27 (84.4%)
Cigarette Smoking
Nonsmokers 43 (34.4%) 12 (38.7%) 0.90
Former Smokers 61 (48.8%) 14 (45.2%)
Current Smokers 21 (16.8%) 5 (16.1%)
Among smokers
Age at Starting (µ ± σ) 25.3 (11.3) 29.6 (14.5) 0.17
Total years (µ ± σ) 29.2 (14.8) 24.6 (16.3) 0.23
Cigs per day (µ ± σ) 24.7 (17.2) 22.7 (20.2) 0.66
Pipe or Cigar smoking
Never 106 (84.8%) 25 (78.1%) 0.40
Ever 19 (15.2%) 7 (21.9%)
Alcohol intake
# of alcoholic drinks per week (µ ± σ) 10.5 (15.6) 12.6 (15.8) 0.50
Other risk factors
Body Mass Index (kg/m2) (µ ± σ) 25.2 (4.3) 25.6 (5.3) 0.64
Leisure Physical Activity Hours/week (µ ± σ) 0.6 (2.6) 0.9 (1.9) 0.69
Daily Fiber Intake Grams/day (µ ± σ) 16.3 (6.9) 16.1 (6.6) 0.86
Daily Fat Intake Grams/day (µ ± σ) 76.4 (39.4) 69.7 (27.9) 0.40
Polyp site
Rectum 19 (16.4%) 9 (29.0%) <0.01
Distal 51 (44.0%) 19 (61.3%)
Proximal 46 (39.7%) 3 (9.7%)
* P value from analysis of variance for continuous variables and for chi-square tests for categorical variables.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
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Table 2: Age adjusted odds ratios by p53 status relative to polyp-free controls.
No p53 protein overexpression p53 protein overexpression
Cigarette Smoking
Never 1.0 1.0
Former 1.3 (0.8–2.1) 1.1 (0.5–2.5)
Current 1.7 (0.9–3.2) 1.6 (0.5–4.8)
Total number of years smoking*
< 15 years 1.4 (0.7–2.7) 2.2 (0.8–6.4)
15 – 29 years 0.9 (0.5–1.7) 0.9 (0.3–2.7)
30+ years 1.8 (1.1–2.9) 1.1 (0.4–2.8)
Pipes or cigars
Never 1.0 1.0
Ever 1.0 (0.5–1.7) 1.6 (0.7–3.9)
Alcohol
Nondrinkers 1.0 1.0
Beer 1–7 bottles/week 1.6 (0.9–2.6) 0.4 (0.1–1.9)
Beer 8+ bottles/week 2.2 (1.0–4.7) 4.5 (1.6–12.4)
Wine (any wine during week) 1.2 (0.8–1.8) 0.8 (0.4–1.8)
Liquor (any liquor during week) 1.2 (0.8–1.8) 1.0 (1.0–4.2)
Total alcohol (wine+beer+liquor)
1–13 drinks/week 1.1 (0.7–1.8) 0.8 (0.3–2.1)
14+ drinks/week 1.5 (0.9–2.6) 2.4 (1.0–5.7)
Body Size and Physical Activity
Body mass index (kg/m2)
< 22.5 1.0 1.0
22.5 – <25.5 1.1 (0.8–2.3) 1.2 (0.5–3.7)
25.5+ 2.0 (1.2–3.3) 1.7 (0.7–4.3)
Leisure physical activity
None 1.0 1.0
2–4 hours/week 0.5 (0.2–1.4) 0.5 (0.1–3.5)
5+ hours/week 0.8 (0.4–1.6) 1.3 (0.5–3.7)
Dietary variables
Fiber: < 12.5 grams/day 1.0 1.0
12.5 – <17 grams/day 0.9 (0.5–1.5) 0.3 (0.1–1.1)
17+ grams/day 1.1 (0.7–1.9) 0.9 (0.4–2.2)
Fat: < 60 grams/day 1.0 1.0
60 – <85.5 grams/day 0.7 (0.4–1.2) 1.6 (0.6–3.9)
85.5 grams/day 1.1 (0.7–1.8) 1.2 (0.5–3.3)
Table 3: Multivariate adjusted* odds ratios by p53 status relative to polyp-free controls.
No p53 protein overexpres-
sion (-)
p53 protein overexpression 
(+)
Case/Case comparison
(A) Associations using all cases (adenomas, CIS, IM)
Duration of Cigarette 
Smoking
Nonsmoker 1.0 1.0
< 15 years 1.5 (0.7–3.0) 2.1 (0.7–6.4) 1.5 (0.4–4.9)
15 – 29 years 1.0 (0.5–1.8) 0.9 (0.3–2.8) 0.9 (0.3–3.1)
30+ years 1.8 (1.1–2.9) 1.0 (0.4–2.6) 0.6 (0.2–1.5)
Pipes or cigars
Never 1.0 1.0
Ever 0.6 (0.3–1.2) 1.3 (0.4–4.0) 2.1 (0.7–6.9)
Beer Consumption
Nondrinker 1.0 1.0
1–7 bottles/week 1.5 (0.9–2.5) 0.4 (0.1–1.9) 0.3 (0.1–1.4)
8+ bottles/week 1.6 (0.7–3.7) 4.0 (1.3–12.0) 2.5 (0.7–8.1)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
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press p53 protein relative to those without overexpression
was over two-fold but not statistically significant (OR =
2.5, 95% CI = 0.7–8.1). Comparison of long duration of
cigarette smoking for subjects with polyps that overex-
press p53 protein relative to those without overexpression
was 0.6 (95%CI = 0.2–1.5).
In addition to these main analyses, we conducted sensitiv-
ity analyses a more strigent (intensity score strong and at
least 25% or more of cells showing evidence of overex-
pression) as well as a less stringent definition (intensity
score of moderate or strong with at least 10% or more of
cells showing evidence of overexpression) of p53 protein
positivity. These analyses, reported in Table 4 suggested
that the findings for long duration of cigarette smoking
were robust to changes in the definition of p53 positivity
whereas the alcohol findings were not robust to changes
in the definition. Specifically, the association seen with
heavy alcohol consumption was only seen using our a
priori definition for positivity and the more stringent defi-
Body Size
Body mass index (kg/m2)
< 22.5 1.0 1.0
22.5 – <25.5 1.2 (0.7–2.1) 1.2(0.4–3.5) 1.1 (0.4–3.3)
25.5+ 1.8 (1.0–3.1) 1.5 (0.6–4.2) 0.9 (0.3–2.5)
(B) Associations using all only cases with advanced adenomas (CIS and IM)
Duration of Cigarette 
Smoking
Nonsmoker 1.0 1.0
< 15 years 1.1 (0.4–2.8) 2.7 (0.8–9.6) 2.5(0.6–11.7)
15 – 29 years 0.7 (0.3–1.7) 0.7 (0.2–2.7) 1.0 (0.2–4.5)
30+ years 1.9 (1.0–3.5) 0.9 (0.3–2.8) 0.5 (0.2–1.7)
Pipes or cigars
Never 1.0 1.0
Ever 0.5 (0.2–1.2) 1.5 (0.4–5.5) 2.9(0.6–12.9)
Beer Consumption
Nondrinker 1.0 1.0
1–7 bottles/week 0.9 (0.4–2.0) 0.3 (0.04–2.4) 0.3(0.04–2.9)
8+ bottles/week 1.4 (0.5–3.8) 4.1 (1.2–14.4) 3.0(0.7–13.2)
Body Size
Body mass index (kg/m2)
< 22.5 1.0 1.0
22.5 – <25.5 0.8 (0.4–1.7) 1.4(0.4–4.8) 1.7 (0.4–6.7)
25.5+ 1.3 (0.7–2.6) 2.2 (0.7–7.0) 1.7 (0.5–6.1)
*age, age2, gender, race, and the other variables listed in the table.
Table 4: Sensitivity analyses altering the definition of p53 positivity.
Original a priori definition a More stringent definition b Less stringent definition c
Long duration of Cigarette Smoking 
(30+ years)
No p53 protein overexpression 1.8 (1.1–2.9) 1.8 (1.1–2.9) 2.1 (1.1–4.3)
p53 protein overexpression 1.0 (0.4–2.6) 0.9 (0.3–2.7) 1.4 (0.8–2.4)
Case/Case Comparison 0.6 (0.2–1.5) 0.5 (0.2–1.6) 0.6 (0.3–1.4)
Heavy Beer Consumption (8 + bottles 
per week)
No p53 protein overexpression 1.6 (0.7–3.7) 1.5 (0.7–3.5) 2.4 (0.9–6.5)
p53 protein overexpression 4.0 (1.3–12.0) 4.9 (1.5–15.8) 1.8 (0.8–4.3)
Case/Case Comparison 2.5 (0.7–8.1) 3.2 (0.9–11.1) 0.8 (0.3–2.3)
aOriginal definition: intensity score of strong and at least 10% or more of cells showing evidence of overexpression bMore stringent definition: 
intensity score of strong and at least 25% or more of cells showing evidence of overexpression cLess stringent definition: intensity score of 
moderate or strong and at least 10% or more of cells showing evidence of overexpression
Table 3: Multivariate adjusted* odds ratios by p53 status relative to polyp-free controls. (Continued)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
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nition of positivity, it was not seen using the more liberal
definition of positivity.
Discussion
The p53 tumor suppressor gene is a commonly mutated
gene in colorectal cancer [3]. While the effect of p53 muta-
tions on colorectal cancer prognosis has been heavily
studied, less is known about how epidemiologic risk fac-
tors such as alcohol and tobacco consumption relate to
p53 status. In many populations, colorectal adenomas are
common [16,24] but most adenomas will not advance to
cancer. Understanding risk factors for early colorectal neo-
plasia is therefore is crucial to colon cancer prevention
[18].
p53 status and polyp site
In this study, adenomatous polyps overexpressing p53
protein (with and without CIS and IM) were more likely
to be found in the rectum and distal colon than in the
proximal colon (p< 0.01). This findings agrees with a
study by Diez and colleagues of invasive colorectal cancer
which also found p53 overexpression more frequently in
distal than proximal tumors (58.5% versus 41.7%, p =
0.03)[25].
p53 status and cigarette smoking
We also found that long duration of cigarette smoking was
related to adenomatous polyps (with and without CIS
and IM) that did not overexpress p53 protein (OR = 1.8,
95% CI = 1.1–2.9) but not those polyps that did overex-
press p53 protein. This association persisted when only
examining CIS and IM cases compared to control and was
robust to different definitions of p53 positivity. This find-
ing also closely matches that of Freedman and colleagues
in their case-control study of invasive colorectal cancer:
OR = 1.84 (95% CI, 1.00–3.37) with heavy cigarette
smoking (40+ pack years) for p53 negative colorectal can-
cer and no association with p53 positive colorectal cancer
as determined by protein overexpression [26]. Our find-
ings also lend support to recent findings by Slattery and
colleagues on the association between cigarette smoking
and microsatellite instability (MSI) positive invasive
colon cancers (OR = 1.6, 95%CI = 1.0–2.5 for men, OR =
2.2, 95%CI = 1.4–3.5 for women) but not MSI negative
cancers[27]. MSI and p53 are inversely associated suggest-
ing two molecularly distinct forms of colorectal cancer,
MSI-positive and MSI-negative, or, as referred to by Lau-
rent-Puig, LOH (loss of heterozygosity)-positive,
characterized by K-ras and p53 mutations, and MSI-posi-
tive colorectal cancers [28,29].
The association between cigarette smoking and p53-nega-
tive tumors is interesting in light of the relationship
between smoking, p53 mutation, and other tumor sites
[30]. People with p53 mutations who smoke may be more
likely to get another cancer, as p53 mutations are associ-
ated with a number of tobacco-related tumors including
lung, head and neck, and bladder cancers [30]. Most of
the p53 mutations in colonic tissue, however, are endog-
enous [4,31] (i.e., spontaneous transitions at the CpG
sites); endogenous mutations are not thought to be asso-
ciated with exogenous environmental factors like cigarette
smoking [4].
p53 status and alcohol intake
We found alcohol intake, specifically heavy beer con-
sumption, to be more associated with polyps that overex-
press p53 than those that do not (OR = 4.0, 95% CI = 1.3–
12.0 for p53 protein overexpression relative to polyp-free
controls versus OR = 1.6, 95%CI = 0.7–3.7). A similar
association was found when restricting the analyses to just
the advanced adenomas (CIS and IM). Sensitivity analy-
ses, however, revealed that this finding was limited to our
a priori definition of p53 positivity as well as a more stri-
gent definition of positivity but not to a less strigent defi-
nition of positivity. Our finding with heavy alcohol
consumption agrees with those of Fredrickson and col-
leagues who reported an increased association of p53-pos-
itive (as determined by protein overexpression) invasive
colorectal cancer with alcohol use (OR = 3.4, 95%CI =
1.1–10)[32].
The association between p53 protein overexpression and
alcohol intake in the colon is interesting in light of the
fact, as previously mentioned, that most p53 mutations in
the colon are transitions rather than transversions. In con-
trast, other tumors such as those of the aerodigestive tract,
which are highly associated with smoking and alcohol
intake [33] have a higher prevalence of transversions [34].
This suggests the possibility of a different mechanism for
alcohol in the colon than aerodigestive tract tumors.
Strengths and Limitations
Our main findings that 1) polyps overexpressing p53 pro-
tein are more likely to be located in the distal colon and
rectum, 2) long-term cigarette smoking is more likely to
be related to early colorectal tumors that do not overex-
press p53 protein, and 3) alcohol consumption, specifi-
cally beer consumption, is more likely to be associated
with early colorectal tumors that overexpress p53 protein,
all agree with the literature on invasive colorectal cancer.
This suggests that underlying mechanisms that may
explain associations between epidemiologic risk factors
and p53 status are likely involved in early colorectal neo-
plasia as well.
Our study benefited from uniform pathologic review and
classification of all lesions, reducing the degree of meas-
urement error in the classification of lesions [35]. p53 sta-
tus was also assessed in a blinded fashion. We were ableBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/29
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to obtain paraffin-embedded tissue blocks for 75% of the
IM cases and 80% of the CIS cases. Risk factor data did not
differ between those with tumor blocks available and
those without (data not shown). Uniform classification,
blinded assessment, and lack of selection bias in tumor
block availability are strengths of this study.
Despite the agreement with the invasive cancer literature
and the other study strengths, there are some limitations
that warrant discussion. Tests of statistical heterogeneity
were not significant. Thus, even though findings between
p53 status and the risk factors were significant relative to
polyp-free controls, tests comparing the odds ratios
between subjects with p53  protein overexpression and
those without were not statistically significant. Measure-
ment error of p53 protein overexpression likely hampered
the ability to detect heterogeneity [36]. Third, we were
limited by a small sample size to fully model differences
stratified by p53  status and case group (adenomatous
polyp, CIS, and IM). However, univariate assessment
between risk factors and p53 status stratified by case group
suggested similar associations irrespective of case group.
Restriction of our final model to just cases with CIS and
IM also did not alter any of our conclusions. As well, reli-
ability analyses suggest that CIS and IM cases should be
combined into a case group of "advanced adenomas"
given the difficulty in reliably classifying these lesions
[35].
Conclusion
In sum, we found similar associations between p53 status
and polyp site, cigarette use, and alcohol consumption
reported in several studies of invasive colorectal cancer.
Specifically, p53 protein overexpression, which has been
associated with a worse overall survival after cancer diag-
nosis, is more likely to be found in polyps in the distal
colon and rectum, more likely to be associated with alco-
hol intake, and less likely to be associated with cigarette
smoking. We did not find any association between p53
status and other risk factors for colorectal neoplasia such
as body size and physical activity. Additional studies of
early colorectal neoplasia that investigate associations
between epidemiologic risk factors and markers of genetic
changes are needed to understand progression to invasive
cancer from a relatively common precursor lesion. How-
ever, this study lends itself to the view that some colorectal
risk factors may share the same association with respect to
specific genotypic changes in precursor lesions and inva-
sive cancer.
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